VENTANA CLDN18 (43-14A) RxDx Assay* is a qualitative immunohistochemical assay intended for laboratory use in the assessment of Claudin 18 (CLDN18) protein in formalin fixed, paraffin-embedded (FFPE) gastric adeno- carcinoma including gastroesophageal junction (GE J) tissue stained with OptiView DAB IHC Detection Kit on a BenchMark ULTRA IHC/ISH instrument.
1 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: CancerToday. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today. Accessed 20 September 2024. 2 Brenner et al. Projected estimates of cancer in Canada in 2024, CMAJ, May 13, 2024, Volume 196, Issue 18, doi: 10.1503/cmaj.240095
1 Astellas press release, Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium. https://www.astellas.com/en/news/26946. Accessed June 12, 2023. 2 Astellas press release, Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series. https://www.astellas.com/en/news/27481. Accessed June 12, 2023. 3 Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401(10389):1655-1668.4 Shah, M.A., Shitara, K., Ajani, J.A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023;29:2133-2141.
1 Roche. VENTANA CLDN18 (43-14A) RxDx Assay, Package Insert (1021574EN Rev A), 2024.2 Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab + mFOLFOX6 as 1L treatment for patients with CLDN18.2+/HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary phase 3 results from SPOTLIGHT. Presented at: ASCO Gastrointestinal Cancers Symposium; January 19-21, 2023; San Francisco, CA. 3 Xu R, Shitara K, Ajani J, et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2- locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary phase 3 results from GLOW. Presented at: ASCO March Plenary Session; March 22, 2023. 4 Hong JY, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020 May;9(5):3367-3374.
Self-paced digital training program that will include:
●Biology and background on the assay
●Guided interpretation of the assay
●Interactive mini-test on scoring sample cases
* Please refer to the VENTANA CLDN18 (43-14A) RxDx Assay method sheet for the full intended use statement and approved therapeutic labeling
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.